92 related articles for article (PubMed ID: 29137288)
1. Elevated TIMP-1 expression is associated with a prometastatic phenotype, disease relapse, and poor survival in neuroblastoma.
Paul P; Rellinger EJ; Qiao J; Lee S; Volny N; Padmanabhan C; Romain CV; Mobley B; Correa H; Chung DH
Oncotarget; 2017 Oct; 8(47):82609-82620. PubMed ID: 29137288
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator inhibitor-2, but not cystatin C, inhibits the prometastatic activity of tissue inhibitor of metalloproteinases-1 in the liver.
Kopitz C; Gerg M; Gansbacher B; Krüger A
Hum Gene Ther; 2008 Oct; 19(10):1039-49. PubMed ID: 18681831
[TBL] [Abstract][Full Text] [Related]
3. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
4. [A novel human DNA sequence with tumor metastasis suppressive activity].
Ge X; Lu Y; Fu S
Zhonghua Zhong Liu Za Zhi; 1999 May; 21(3):182-5. PubMed ID: 11776830
[TBL] [Abstract][Full Text] [Related]
5. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.
Fabian J; Lodrini M; Oehme I; Schier MC; Thole TM; Hielscher T; Kopp-Schneider A; Opitz L; Capper D; von Deimling A; Wiegand I; Milde T; Mahlknecht U; Westermann F; Popanda O; Roels F; Hero B; Berthold F; Fischer M; Kulozik AE; Witt O; Deubzer HE
Cancer Res; 2014 May; 74(9):2604-16. PubMed ID: 24419085
[TBL] [Abstract][Full Text] [Related]
6. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
[TBL] [Abstract][Full Text] [Related]
7.
Dzieran J; Rodriguez Garcia A; Westermark UK; Henley AB; Eyre Sánchez E; Träger C; Johansson HJ; Lehtiö J; Arsenian-Henriksson M
Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1229-E1238. PubMed ID: 29374092
[TBL] [Abstract][Full Text] [Related]
8. A Metastatic Mouse Model Identifies Genes That Regulate Neuroblastoma Metastasis.
Seong BK; Fathers KE; Hallett R; Yung CK; Stein LD; Mouaaz S; Kee L; Hawkins CE; Irwin MS; Kaplan DR
Cancer Res; 2017 Feb; 77(3):696-706. PubMed ID: 27899382
[TBL] [Abstract][Full Text] [Related]
9. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
10. High Skp2 expression characterizes high-risk neuroblastomas independent of MYCN status.
Westermann F; Henrich KO; Wei JS; Lutz W; Fischer M; König R; Wiedemeyer R; Ehemann V; Brors B; Ernestus K; Leuschner I; Benner A; Khan J; Schwab M
Clin Cancer Res; 2007 Aug; 13(16):4695-703. PubMed ID: 17652624
[TBL] [Abstract][Full Text] [Related]
11. L1-CAM knock-down radiosensitizes neuroblastoma IMR-32 cells by simultaneously decreasing MycN, but increasing PTEN protein expression.
Rached J; Nasr Z; Abdallah J; Abou-Antoun T
Int J Oncol; 2016 Oct; 49(4):1722-30. PubMed ID: 27432152
[TBL] [Abstract][Full Text] [Related]
12. Loss of TIMP-3 promotes tumor invasion via elevated IL-6 production and predicts poor survival and relapse in HPV-infected non-small cell lung cancer.
Wu DW; Tsai LH; Chen PM; Lee MC; Wang L; Chen CY; Cheng YW; Lee H
Am J Pathol; 2012 Nov; 181(5):1796-806. PubMed ID: 22982189
[TBL] [Abstract][Full Text] [Related]
13. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
14. FOXP1 inhibits cell growth and attenuates tumorigenicity of neuroblastoma.
Ackermann S; Kocak H; Hero B; Ehemann V; Kahlert Y; Oberthuer A; Roels F; Theißen J; Odenthal M; Berthold F; Fischer M
BMC Cancer; 2014 Nov; 14():840. PubMed ID: 25406647
[TBL] [Abstract][Full Text] [Related]
15. Stable knockdown of MYCN by lentivirus-based RNAi inhibits human neuroblastoma cells growth in vitro and in vivo.
Jiang R; Xue S; Jin Z
Biochem Biophys Res Commun; 2011 Jul; 410(2):364-70. PubMed ID: 21683062
[TBL] [Abstract][Full Text] [Related]
16. The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells.
O'Brien EM; Selfe JL; Martins AS; Walters ZS; Shipley JM
BMC Cancer; 2018 Feb; 18(1):217. PubMed ID: 29466962
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression.
Hofmann UB; Westphal JR; Waas ET; Zendman AJ; Cornelissen IM; Ruiter DJ; van Muijen GN
Br J Cancer; 1999 Nov; 81(5):774-82. PubMed ID: 10555745
[TBL] [Abstract][Full Text] [Related]
18. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
[TBL] [Abstract][Full Text] [Related]
19. Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity.
Schweigerer L; Breit S; Wenzel A; Tsunamoto K; Ludwig R; Schwab M
Cancer Res; 1990 Jul; 50(14):4411-6. PubMed ID: 2364393
[TBL] [Abstract][Full Text] [Related]
20. Lack of suppression of tumor cell phenotype by overexpression of TIMP-3 in mouse JB6 tumor cells identification of a transfectant with increased tumorigenicity and invasiveness.
Sun Y; Kim H; Parker M; Stetler-Stevenson WG; Colburn NH
Anticancer Res; 1996; 16(1):1-7. PubMed ID: 8615593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
